Oct 31 (Reuters) - Spectral Medical Inc EDT.TO :
* Spectral provides update on FDA meeting regarding its pma submission for toraymyxin(tm)
* Spectral Medical - meeting with fda consisted of discussion of issues identified by FDA for toraymyxin after first 100 days of review
* Spectral Medical - co committed to a timely response to fda's questions, which is expected to occur during month of November 2017